Tumor Ablation Market Size, Share & Trends Analysis Report By Technology (Radiofrequency, Microwave), By Treatment (Surgical, Laparoscopic), By Application (Liver Cancer), By Region, And Segment Forecasts, 2025 - 2030

Tumor Ablation Market Size & Trends

The global tumor ablation market size was estimated at USD 1.89 billion in 2024 and is projected to grow at a CAGR of 13.8% from 2025 to 2030. The rising prevalence of cancer and high demand for safer therapeutic options are major factors contributing to the market growth. According to the WHO, it is projected that around 10-11 million cancer cases will be diagnosed each year globally till 2030. Lucrative growth potential in currently available therapeutic options, and high demand for minimally and non-invasive therapies are the factors expected to drive the market growth in upcoming years.

The growing preference among both surgeons and patients for minimally invasive surgical procedures, due to their advantages like faster recovery, enhanced patient comfort, and reduced procedure time, is anticipated to be a key driver for the increased demand in advanced tumor ablation techniques. Advanced tumor ablation procedures are generally performed on an outpatient basis and do not require any hospital admission compared with conventional therapies, thereby reducing the total healthcare cost. The ablative surgeries are the preferred therapy for tumors of smaller sizes. Thus, its procedural volume is indirectly dependent on the yearly cancer screening rates. Since the number of newly diagnosed cancer cases has dropped significantly during COVID-19 owing to fewer screening initiatives undertaken by concerned authorities.

Technological advancements to enhance accuracy, portability, and cost-effectiveness are the factors that enhance market players to constantly improve and launch advanced tumor ablation devices. Image-guided equipment, HIFU, and cryoablation are major examples of these technological advancements. The utilization of internally cooled radiofrequency probes in the cooled radiofrequency denervation technique to expand the lesion's size is an emerging method that is expected to have a substantial impact on the market growth. This technique enables complete denervation of the sacroiliac joint which helps in pain management.

Market Concentration & Characteristics

The global tumor ablation industry is characterized by a high degree of innovation, with new technologies and methods being developed and introduced at regular interval.

Several market specific players such as Boston Scientific Corporation, Johnson & Johnson Service Inc., Bioventus Inc., and EDAP TMS are involved in merger and acquisition activities. Through M&A activity, these companies can expand their geographic reach and enter into new markets.

Companies need to invest substantial resources in clinical trials and regulatory submissions in order to obtain regulatory approval for their products. This may increase the cost of developing novel tumor ablation technologies.

A wide range of product substitutes are available as tumor ablation is a relatively new and rapidly evolving field of medicine, and there is a need for a variety of treatment options to meet the patient's needs with different types of cancer.

The end-user concentration in the tumor ablation industry is likely to increase in the coming years as larger companies have more resources to invest in product development and innovation, and they are also able to reach a wide range of customers.

Technology Insights

Based on technology, the radiofrequency tumor ablation segment led the market with the largest revenue share of 32.8% in 2024. The dominance can be attributed to its advantages, such as specificity and efficiency in solid tumor ablation procedures in the kidney and liver. In addition, radiofrequency ablation can be used to treat multiple tumors at the same time, thus improving procedural efficiency with the use of multiple electrodes placed at different sites. This is expected to boost the adoption rate of advanced tumor ablation techniques.

The success rate of radiofrequency/microwave ablation technology in eliminating small liver tumors is estimated to be greater than 85%. According to the NCBI report, recurrence of tumors in patients opting for surgical resection ranges from 30% to 70%. On the other hand, tumor recurrence is very low (0.7-8%) in cases of radiofrequency ablation for similar tumors. The advantages of radiofrequency techniques to successfully treat tumors at early stages are expected to drive market growth during the forecast period.

The microwave ablation technology segment is anticipated to witness at the fastest CAGR over the forecast period. The energy of a microwave (MW) ablation device propagates an electromagnetic field, unlike electric current in a radiofrequency ablation device. This improves the application of microwave ablation technology in tissue with low electrical conductance, such as bones and lungs. Major benefits of this technology include larger tumor ablation volume, consistency in high temperature, low ablation pain, and optimal heating of the cystic mass. These benefits are anticipated to support the growth of this segment. Furthermore, minimum procedure time (5-10 minutes), improved efficacy with minimal complications, and reduced hospital stay are expected to drive the segment growth.

Treatment Insights

Based on technology, the percutaneous ablation segment accounted for the largest revenue share in 2024. These procedures offer faster recovery, minimal scarring, and increased safety. In addition, factors such as quick surgery time, patient comfort, and cost-efficiency are anticipated to further boost the segment demand. However, higher complications associated with the system are anticipated to limit its growth, especially in the hospitals lacking skilled professionals.

The laparoscopic ablation segment is estimated to register at the fastest CAGR over the forecast period. According to the NCBI report, percutaneous ablations are not feasible in about 25-55% of patients due to unfavorable tumor locations. The tumor recurrence rate is higher in percutaneous ablation, due to insufficient ablation of the tumors located deep inside the tissue. In addition, percutaneous ablation is contraindicated in treating lesions that are very adjacent to the gastrointestinal tract, gall bladder, bile duct, and heart due to the high risk of tumor recurrence. Therefore, in such cases, laparoscopic ablation is efficient in providing long-term outcomes while simultaneously retaining minimal invasiveness. This is expected to boost the laparoscopic ablation segment growth during the forecast period.

Application Insights

Based on application, the other segments accounted for the largest market share in 2024. The other segment includes various types of cancer, such as bone metastasis and ENT cancer. The availability of advanced methods and increasing cancer prevalence are anticipated to facilitate market growth.

The lung cancer segment is anticipated to grow at the fastest CAGR during the forecast period, owing to the increasing cases of lung cancer globally due to the rising prevalence of smoking as tobacco use remains the leading cause of lung cancer. For instance, according to the WHO, tobacco smoking is the primary factor behind lung cancer, accounting for roughly 85% of all reported cases.

The kidney cancer segment is anticipated to grow at a rapid CAGR during the forecast period. Radiofrequency and microwave ablation technology are effective in the treatment of renal tumors. Patients having solitary kidneys, tumor size (less than 4cm), and a slow post-surgical recovery rate are prospects for ablation of kidney tumors. According to the American Cancer Society’s estimates for 2022 suggest that 79,000 new cases of renal cancer will be diagnosed. In addition, with the increasing use of medical imaging, the number of diagnosed cases is expected to increase, driving the demand for treatment procedures during the forecast period.

Regional Insights

North America dominated the tumor ablation market with the largest revenue share of 34.33% in 2024. Major factors contributing to the growth of this region include government support for quality healthcare, high purchasing power parity, availability of reimbursements, and increasing prevalence of cancer. For instance, in the U.S., the Patient Protection and Affordable Care Act (PPACA), promotes the quality and affordability of healthcare through health coverage policies that reduce the cost of healthcare for individuals and the government. In addition, the precision medicine initiative in formulating tailored strategies on unique characteristics of diseases. Hence, such government initiatives are anticipated to improve the overall healthcare system, thus boosting market growth.

U.S. Tumor Ablation Market Trends

The tumor ablation market in the U.S. accounted for the largest market share in North America in 2024. Growing incidence of cancer and growing awareness regarding early disease diagnosis are some of the major factors anticipated to foster the country's growth. For instance, according to the American Cancer Society, in 2023, approximately 1,958,310 new cancer cases are expected to be diagnosed in the U.S., and around 609,820 patients may die due to the same. Hence, various initiatives undertaken by the American Cancer Society to create awareness about cancer types are expected to drive the adoption of diagnostic and treatment procedures for these diseases.

Europe Tumor Ablation Market Trends

The tumor ablation market in Europe held a significant market share in 2024. A greater extent of public funding in Europe’s healthcare system has contributed to this growth. Moreover, the growing geriatric population coupled with government support to control cancer is estimated to boost the market growth in this region. For instance, the European Cancer Observatory aims to create awareness about cancer, early diagnostic techniques, and advanced, minimally invasive therapeutic options.

Asia Pacific Tumor Ablation Market Trends

The tumor ablation market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The surge in patient numbers and the increasing presence of prominent healthcare providers in swiftly developing economies like India and China create avenues for expansion. Furthermore, the Asia Pacific region is witnessing improvements in healthcare utilization with government support. For example, the Indian government extends financial aid to indigent cancer patients through the Health Minister Cancer Patient Fund (HMCPF) scheme. This is expected to stimulate the demand for tumor ablation devices, fostering the region's growth.

The Japan tumor ablation market is anticipated to grow at a significant CAGR during the forecast period. Japan’s healthcare system is witnessing a transition in service portfolio from nursing care to preventive care in disease management because of rising healthcare expenditure. In addition, the increasing prevalence of cancer, rising government initiatives for better healthcare infrastructure, and benefits associated with tumor ablation in the country are among the factors expected to propel market growth.

The tumor ablation market in China accounted for the largest market share in Asia Pacific in 2024, due to increasing cancer cases and a growing preference for safe & effective surgical ablation procedures. Many studies in China are adopting tumor ablation procedures as an alternative treatment to conventional surgical treatments, which is expected to boost the market growth.

Key Tumor Ablation Company Insights

Medtronic, Boston Scientific Corporation, Johnson & Johnson Service Inc., and AngioDynamics are some of the dominant players operating in the tumor ablation industry.

• Medtronic has a global presence and operates from over 370 locations in approximately 160 countries.

• Boston Scientific Corporation operates and markets across three reportable segments such as MedSurg, rhythm & neuro, and cardiovascular.

• AngioDynamics operates at several facilities across the U.S., Asia, Europe, and Latin America and has reached more than 50 markets through direct sales and distributors.

Bioventus Inc. (Misonix Inc.), EDAP TMS, Chongqing Haifu Medical Technology Co., Ltd, HealthTronics, Inc., and H.S. Hospital Service S.p.A. are some of the emerging market players functioning in the tumor ablation industry.

• Mermaid Medical’s sales force works in 10 offices across the U.S., Asia, and Europe, and supplies medical devices to various end users, such as hospitals.

• H.S. Hospital Service S.p.A. has varied lines of business, including distribution of surgical & other medical apparatus, equipment, and instruments.

Recent Developments

• In August 2023, Bioventus Inc. (Misonix Inc.) received U.S. FDA clearance for its neXus SonaStar Elite handpiece for various procedures, including removing malignant & benign spinal and brain tumors.

• In July 2023, EDAP TMS received reimbursement approval in Switzerland for using HIFU to treat prostate cancer.

• In April 2023, Johnson & Johnson Service Inc., announced that the first patient was treated in North America in its clinical Investigational Device Exemption (IDE) trial to evaluate the safety and efficacy of transbronchial microwave ablation using the NEUWAVE FLEX microwave ablation system.

• In April 2023, Johnson & Johnson Services, Inc. announced that the first patient was treated in North America in its clinical Investigational Device Exemption (IDE) trial to evaluate the safety and efficacy of transbronchial microwave ablation using the NEUWAVE FLEX microwave ablation system.

• In March 2023, AngioDynamics entered a new partnership with Minimax Medical for the worldwide distribution of its product portfolio.

Tumor Ablation Market Report Scope

Global Tumor Ablation Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global tumor ablation market report based on the technology, treatment, application, and region:

• Technology Outlook (Revenue in USD Million, 2018 - 2030)

  • Radiofrequency ablation

  • Microwave ablation

  • Cryoablation

  • Irreversible electroporation ablation

  • HIFU

  • Other ablation technologies

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Surgical ablation

  • Laparoscopic ablation

  • Percutaneous ablation

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Kidney Cancer

  • Liver cancer

  • Breast cancer

  • Lung cancer

  • Prostate cancer

  • Other cancer

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait